Join the 'Hepatitis C' group to help and get support from people like you.

Hepatitis C Blog

Related terms: Hepatitis C, Chronic, Chronic Hepatitis C, Hep C

Pricey Hepatitis Drug a Good Bet in U.S. Prisons, Study Says

Posted 3 days ago by Drugs.com

MONDAY, Oct. 20, 2014 – Using an expensive drug to treat prison inmates with hepatitis C is more cost-effective than another treatment option, according to a new study. More than 500,000 prison inmates in the United States have hepatitis C, which causes liver damage. It's spread by contact with infected blood. The drug Sovaldi (sofosbuvir) costs more than $7,000 a week for 12 weeks of treatment. Some states are concerned about the price and want to limit its use in prisons. However, "it looks like the additional benefits of sofosbuvir are sufficiently large even in this high-risk population to justify its increased cost," study senior author Jeremy Goldhaber-Fiebert, an assistant professor of medicine at the Stanford School of Medicine, said in a university news release. Until a few years ago, hepatitis C patients were treated over 48 weeks with two drugs, pegylated interferon and ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir

FDA Approves Harvoni (ledipasvir and sofosbuvir) for Hepatitis C

Posted 9 days ago by Drugs.com

October 10, 2014 – The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection. Both drugs in Harvoni interfere with the enzymes needed by HCV to multiply. Sofosbuvir is a previously approved HCV drug marketed under the brand name Sovaldi. Harvoni also contains a new drug called ledipasvir. “With the development and approval of new treatments for hepatitis C virus, we are changing the treatment paradigm for Americans living with the disease,” said Edward Cox, M.D., M.P.H., director of the Office of Antimicrobial Products in the FDA’s Center for Dr ... Read more

Related support groups: Hepatitis C, Sofosbuvir

Hepatitis C Could Become Rare Disease in 20 Years: Study

Posted 4 Aug 2014 by Drugs.com

MONDAY, Aug. 4, 2014 – The once tough-to-treat liver infection hepatitis C could become a rare disease in the United States in the next two decades, a new study estimates. Hepatitis C, a viral infection that harms the liver, is usually passed through infected blood. For most people, the infection becomes chronic and it can eventually lead to scarring of the liver (cirrhosis) or liver cancer. U.S. health officials estimate that over 3 million Americans currently have chronic hepatitis C – most of whom don't know it because the infection usually causes no symptoms. But with recent treatment advances, hepatitis C could become rare by 2036, researchers report in the Aug. 5 issue of the Annals of Internal Medicine. "Rare" refers to a disease that affects one in 1,500 people at most, said senior researcher Jagpreet Chhatwal, who conducted the study while at the University of Pittsburgh ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir

HIV Meds May Also Help Control Hepatitis C, Study Finds

Posted 23 Jul 2014 by Drugs.com

WEDNESDAY, July 23, 2014 – For patients infected with both HIV and hepatitis C, HIV antiretroviral therapy may help control both viruses, a small study suggests. Researchers said doctors could use their findings to improve treatment strategies for people with the two diseases. "The findings suggest that HIV suppression with antiretroviral medications plays an important role in the management of individuals with [hepatitis C] and HIV infection," said study leader Dr. Kenneth Sherman, a professor of medicine at the University of Cincinnati College of Medicine. "It supports the concept that in those with HCV/HIV infection, early and uninterrupted HIV therapy is a critical part of preventing liver disease." The researchers conducted the study to address concerns that treating patients who have HIV – the AIDS-causing virus – and hepatitis C with HIV antiretroviral therapy would damage the ... Read more

Related support groups: Hepatitis C, HIV Infection

Hepatitis C Infection May Have 'Silver Lining' for Transplant Patients

Posted 25 Jun 2014 by Drugs.com

WEDNESDAY, June 25, 2014 – The liver-damaging hepatitis C virus may come with an unexpected benefit for patients who need a liver transplant due to the infection, a new European study reports. The virus appears to restrain a dangerous immune system response that can otherwise cause the body to reject the new liver, according to findings published June 25 in Science Translational Medicine. This effect allowed about half of a small group of liver transplant patients to stop taking drugs that suppress their immune system, said lead author Felix Bohne, a postdoctoral fellow with the Institute of Virology at the Technical University of Munich Hemholtz Center Munich, Germany. "It is always a hard thing to translate results from clinical studies into the everyday treatment of patients, but our study clearly shows that hepatitis C-infected liver recipients can discontinue the immunosuppressive ... Read more

Related support groups: Hepatitis C, Organ Transplant

Alcohol Fuels Liver Disease in Those With HIV and Hepatitis C

Posted 7 May 2014 by Drugs.com

WEDNESDAY, May 7, 2014 – People infected with both HIV and hepatitis C are much more likely to develop advanced liver disease if they drink any alcohol at all, according to a new study. Researchers analyzed data from thousands of participants in a Veterans Affairs study on aging and found the risk of advanced liver fibrosis increased overall with alcohol use but was especially striking in patients with both HIV and hepatitis C (co-infected patients). The data included more than 700 people who were infected with both HIV and hepatitis C, more than 1,400 infected with HIV only, nearly 300 infected with hepatitis C only, and nearly 1,160 uninfected people. Among the study participants who were light drinkers, co-infected patients were 13 times more likely than non-infected people to have advanced liver fibrosis. Among participants who were heavy drinkers, co-infected patients were 21 ... Read more

Related support groups: Hepatitis C, HIV Infection, Liver and Pancreatic Disease, Alcoholic Liver Damage, Acute Alcohol Intoxication

Cure Rate for Experimental Hepatitis C Drug Tops 95 Percent

Posted 10 Apr 2014 by Drugs.com

THURSDAY, April 10, 2014 – Researchers report that an experimental drug has cured more than 95 percent of patients infected with hepatitis C, including some who failed other treatments. If it wins approval from the U.S. Food and Drug Administration, this new drug, called ABT-450, could potentially compete with another innovative hepatitis C medication that costs $1,000 a day. Nearly 3 million Americans have hepatitis C, a disease that can cause liver cirrhosis and cancer. These newer, advanced treatments are better-tolerated and easier to take than interferon, the traditional standard treatment for hepatitis C, researchers say. "Interferon is no longer required to cure hepatitis C," said Dr. Stefan Zeuzem, a professor of medicine at the J.W. Goethe University Hospital in Frankfurt, Germany, and lead researcher on the ABT-450 study. His research pairing ABT-450 with other ... Read more

Related support groups: Hepatitis C

Hepatitis C Patients With HIV May Face Higher Risk of Liver Disease

Posted 19 Mar 2014 by Drugs.com

WEDNESDAY, March 19, 2014 – Among people with hepatitis C, the risk of serious liver disease is much higher in those who also have HIV than in those without the AIDS-causing virus, a new study finds. This is true even among patients with HIV who are otherwise benefiting from antiretroviral therapy to treat the virus, the University of Pennsylvania researchers said. They analyzed data from more than 4,200 patients with both hepatitis C and HIV who were receiving antiretroviral therapy. In addition, they looked at data on more than 6,000 patients with hepatitis C only. The patients received care between 1997 and 2010. The HIV/hepatitis C patients had an 80 percent higher rate of serious liver disease than those with hepatitis C only, according to the study, which was published in the March 18 issue of the journal Annals of Internal Medicine. Even HIV/hepatitis C patients who had a good ... Read more

Related support groups: Hepatitis C, HIV Infection

Nearly 3 Million Americans Living With Hepatitis C

Posted 3 Mar 2014 by Drugs.com

MONDAY, March 3, 2014 – More than 2.7 million Americans are currently infected with liver-damaging hepatitis C, federal officials say, and one expert believes that number could be even higher. These individuals are at much higher risk for liver disease, liver cancer and other chronic health issues, experts note. And although there are treatments available that can rid the body of the virus, many Americans remain unaware that they are even infected, according to researchers from the U.S. Centers for Disease Control and Prevention. The long-term consequences of not diagnosing and treating hepatitis C are dire: Experts say more people in the United States now die from infection with hepatitis C than from HIV, the virus that causes AIDS. The new survey of U.S. households, which took place between 2003 and 2010, found the number of people living with hepatitis C has actually fallen by ... Read more

Related support groups: Hepatitis C

Most With Hepatitis C May Soon Find Hope in New Treatments

Posted 15 Jan 2014 by Drugs.com

WEDNESDAY, Jan. 15, 2014 – Hepatitis C treatment isn't pretty, but the dark days of weekly injections, rough side effects and no guarantee of full recovery from the liver-damaging disease may soon be over, researchers report. Two studies, both published in the Jan. 16 issue of the New England Journal of Medicine, involved giving various combinations of antiviral pill cocktails to patients with hepatitis C. Some had failed to respond to standard treatments, and some had not received treatment yet. Yet, the cocktails cleared the virus in both studies for between 93 percent and 98 percent of the patients. These cocktails are game-changers for the illness, said Andrew Muir, director of gastroenterology and hepatology research at the Duke Clinical Research Institute. "This has made me change the way I'm talking with patients. These regimens are essentially going to cure everybody," said ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir

Sovaldi Approved for Chronic Hepatitis C

Posted 9 Dec 2013 by Drugs.com

MONDAY, Dec. 9, 2013 – Sovaldi (sofosbuvir) has been approved by the U.S. Food and Drug Administration to treat chronic infection with Hepatitis C. It's considered a breakthrough medication since it's the first such drug that does not require same-time administration of interferon, the agency said in a news release. Infection with the hepatitis C virus causes liver inflammation that can lead to liver failure. Most infected people have no symptoms for years until the onset of liver failure, the FDA said. Complications may include a yellowing of the eyes and skin called jaundice, liver cancer, bleeding or fluid accumulation in the abdomen. Some 3.2 million Americans are infected with hepatitis C, the agency said. Sovaldi is designed to inhibit a protein that the virus needs to replicate. The drug's safety and effectiveness were evaluated in clinical studies involving 1,947 people who ... Read more

Related support groups: Hepatitis C

New Hepatitis C Drug Sovaldi Approved by FDA

Posted 9 Dec 2013 by Drugs.com

FRIDAY, Dec. 6, 2013 – A new hepatitis C drug that can be taken as a pill once a day was approved by the U.S. Food and Drug Administration on Friday. The drug, called Sovaldi and made by Calif.-based Gilead Sciences Inc., works faster and should be much simpler to take for the millions of Americans who have the virus, which can destroy the liver if left untreated. The FDA said in a statement that Sovaldi is to be taken with older drugs to treat the main forms of hepatitis C. The agency added that 3.2 million Americans have the disease, and people born between 1945 and 1965 are five times more likely to be infected. Current treatments can take almost a year to beat back the virus, and involve weekly injections of the drug interferon, which can cause diarrhea and flu-like symptoms, the FDA said. Only about 75 percent of patients are cured with current treatments. In clinical trials, ... Read more

Related support groups: Hepatitis C

FDA Approves Sovaldi for Chronic Hepatitis C

Posted 6 Dec 2013 by Drugs.com

December 6, 2013 – The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon. “Today’s approval represents a significant shift in the treatment paradigm for some patients with chronic hepatitis C,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. Sovaldi is the second drug approved by the FDA in the past two weeks to treat chronic HCV infection. On November 22, the FDA approved Olysio (simeprevir). Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with HCV have no symptoms of the d ... Read more

Related support groups: Hepatitis C, Chronic Hepatitis C, Hepatitis C, Chronic

FDA Approves Olysio (simeprevir) for Hepatitis C Virus

Posted 24 Nov 2013 by Drugs.com

November 22, 2013 – The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with the hepatitis C virus have no symptoms of the disease until liver damage becomes apparent, which may take several years. Most of these people then go on to develop chronic hepatitis C. Some will also develop scarring and poor liver function (cirrhosis) over many years, which can lead to complications such as bleeding, jaundice (yellowish eyes or skin), fluid accumulation in the abdomen, infections or liver cancer. According to the Centers for Disease Control and Prevention, about 3.2 million Americans are infected with the hepatitis C virus. Olysio is a protease inhibitor that ... Read more

Related support groups: Hepatitis C, Hepatitis C, Chronic

Study Finds Too Few With Hepatitis C Start or Stick With Treatment

Posted 6 Nov 2013 by Drugs.com

WEDNESDAY, Nov. 6 – A new study suggests that only a quarter of people with hepatitis C are willing to start the standard treatment for the serious viral infection. When interferon injections – the current standard treatment – work, which only happens about 16 percent of the time, the risk of dying drops by 45 percent, the University of Southern California researchers said. Unfortunately, the drug doesn't always manage to suppress the virus completely and many people can't tolerate its side effects, which include gastrointestinal problems and anemia. "This study points out the inadequacies of old therapies for hepatitis C," said Dr. Douglas Dieterich, a professor of medicine and liver diseases at the Icahn School of Medicine at Mount Sinai Hospital in New York City. Hepatitis C is a viral infection that causes inflammation of the liver. It's transmitted from person to person via ... Read more

Related support groups: Hepatitis C

Page 1 2 3 4 5 6 Next

Ask a Question

Further Information

Related Condition Support Groups

Infectious Hepatitis

Related Drug Support Groups

Incivek, ribavirin, Sovaldi, Pegasys, Victrelis, PegIntron, interferon alfa-2b, Copegus, Ribasphere, view more... telaprevir, Rebetol, interferon alfa-2a, boceprevir, sofosbuvir, peginterferon alfa-2b, Intron A, Olysio, peginterferon alfa-2a, interferon alfa-2b/ribavirin, Rebetron, simeprevir, RibaPak, Roferon-A, Infergen, interferon alfacon-1, ledipasvir/sofosbuvir, RibaTab